Developing targeted therapies that either restore or activate NURR1 could lead to novel treatment strategies for high-risk neuroblastoma and PD, offering hope for improving patient outcomes and providing new avenues for drug discovery (Table 4). This evidence concerns the gene NR4A2 and neuroblastoma.